ArticleFrontiers in immunology2012
Regulatory effects of C5a on IL-17A, IL-17F, and IL-23.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Ascertaining the mechanistic etiology of COVID-associated glomerulonephritis: a systematic review.Frontiers in medicine · 2025Pooled it
- Therapeutic targeting of interleukin-17C signaling in carcinogenesis of endometriosis.Cell reports. Medicine · 2025Article
- A CD4Immunity · 2025Article
- Interleukin 26 Induces Macrophage IL-9 Expression in Rheumatoid Arthritis.International journal of molecular sciences · 2023Article
- Inside-Out of Complement in Cancer.Frontiers in immunology · 2022Review
- Article
- Article
- C5aR1 Activation Drives Early IFN-γ Production to Control ExperimentalFrontiers in immunology · 2020Article
- Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate.ACR open rheumatology · 2019Article
- Role of the complement system in the tumor microenvironment.Cancer cell international · 2019Review
- Targeting complement-mediated immunoregulation for cancer immunotherapy.Seminars in immunology · 2018Review
- Complement and the Regulation of T Cell Responses.Annual review of immunology · 2018Review
- Emerging role of C5a/C5aR IL-17A axis in cGVHD.American journal of translational research · 2018Article
- Interleukin-17 receptor A (IL-17RA) as a central regulator of the protective immune response against Giardia.Scientific reports · 2017Article
- Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg.Scientific reports · 2017Article
- Keeping It All Going-Complement Meets Metabolism.Frontiers in immunology · 2017Review
- Innate and adaptive immunologic functions of complement in the host response to Listeria monocytogenes infection.Immunobiology · 2016Review
- Cytokine Responses to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients.Inflammation · 2015Article
- Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Complement--tapping into new sites and effector systems.Nature reviews. Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The complement anaphylatoxin, C5a, through binding to its receptors (C5aR or C5L2), has important biological properties for recruitment and activation of phagocytes. C5a has been identified as a powerful modulator of Toll-like receptor-induced cytokine and chemokine production by macrophages. Both the complement system and the interleukin (IL)-17 cytokine family protect against extracellular pathogens by enhancing innate immune functions. On the basis of its concentration, C5a can either positively or negatively modulate the production by macrophages of IL-17 family members as well as IL-23 via the phosphatidylinositol 3-kinase/Akt signaling cascade. C5a can also affect the production and maintenance of IL-17-producing T cells. Using C5a, C5aR, or C5L2 deficiency or blockade, IL-17/IL-23 production and/or IL-17-dependent disease progression has been shown to be substantially modified. The contributions of C5a interaction with its receptors in the production of IL-17/IL-23 and promotion of IL-17-dependent immune responses are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.